GGrantIndex
← Search

Translating Pancreatic Risk into Personalized Medicine. A Meeting of Thought Lea

$20,000R13FY2009DKNIH

University Of Pittsburgh At Pittsburgh, Pittsburgh PA

Investigators

Linked publications & trials

Abstract

DESCRIPTION (provided by applicant): We are proposing a scientific Course and workshop entitled: Translating Pancreatitis Risk into Personalized Medicine. A Meeting of Thought Leaders, Translational Scientists and Young Investigators Dedicated to Cooperative Efforts. The program will have four major sessions aimed at stimulating collaborative research in pancreatic diseases. The program will begin by a review and discussion of the advances made in IBD through the NIDDK IBD-Genetics Consortium. It is intended that both positive and negative lesions learned from this consortium will be applicable to the study of pancreatic diseases. This has been a highly successful group who has been working on diseases that are similar to chronic pancreatitis. This discussion will be followed by a review of the NAPS2 program, with the opportunity to immediately determine the strengths and weaknesses of existing pancreatic resources, and to help in planning for the future. The second session will focus on broader needs identified by the National Commission on Digestive Diseases related to pancreatic disorders. This report has been carefully developed and serves as an important document for program development. After a careful review and discussion of the Report, the investigators who have planned, or who are conducting multi-center trials will have the opportunity to present the study goals and specific aims of their respective studies. Discussion during this session will focus on identifying the needs that are being met, and the identification of major gaps in research planning or opportunities. Session three is more didactic, with the intention of bringing clinical researchers up to date on advances in epidemiology, statistics, population genetics, systems biology and selecting therapeutic targets (chemical genomics). In addition, the issue of developing and using biomarkers

View original record on NIH RePORTER →